Phase II study evaluating the clinical efficacy of TG4010 (MVA-MUC1-IL2) in patients with metastatic Renal Cell Carcinoma (RCC)

×

Foutmelding

  • Notice: Trying to access array offset on value of type null in bootstrap_pager() (regel 53 van /var/www/biosafety.be/sites/all/themes/bootstrap/templates/system/pager.func.php).
  • Notice: Trying to access array offset on value of type null in bootstrap_pager() (regel 95 van /var/www/biosafety.be/sites/all/themes/bootstrap/templates/system/pager.func.php).
Study title: 
Phase II study evaluating the clinical efficacy of TG4010 (MVA-MUC1-IL2) in patients with metastatic Renal Cell Carcinoma (RCC)
EU record number: 
B/BE/02/B7
Pharmaceutical study code: 
TG4010.06
Company / Sponsor: 
Transgene S.A.
Phase: 
II
Treated organism: 
Humans
Indication category: 
Cancer therapy
Disease: 
Progressive metastatic renal cell carcinoma
Therapeutic approach: 
Immunotherapy
Genetic modification: 
sequences coding for the human MUC-1 antigen and IL-2
Method of transfer of nucleic acid of interest: 
Attenuated Vaccinia Virus (Ankara Strain)
Administered biological material: 
Recombinant Attenuated Vaccinia Virus
Route of administration: 
Subcutaneous
Locations in Belgium: 
Bruxelles: Cliniques Universitaires St Luc, Hôpital Erasme
Nr of subjects: 
not specified (up to 32 patients in Europe)
Foreseen duration: 
1 year
Type of procedure: 
Contained use and Deliberate release
Current status: 
Authorized

Information related to the decision procedure